ME-3221 NEW
| Price | $176 | $433 | $592 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-23 |
Product Details
| Product Name: ME-3221 | CAS No.: 139958-16-0 |
| Purity: 99.93% | Supply Ability: 10g |
| Release date: 2026/05/23 |
Product Introduction
Bioactivity
| Name | ME-3221 |
| Description | ME-3221 is an angiotensin AT1 receptor antagonist that prevents hypertensive complications in aged stroke-prone hypertensive rats. |
| In vivo | ME3221 inhibited the pressor response to angiotensin II in rats at doses of 0.3-1.0 mg/kg. Higher doses of ME3221 (3-10 mg/kg) were required to achieve the same inhibitory potency in dogs.The antagonistic potency of ME3221 against angiotensin II-induced contraction in rabbit aorta (pA2 = 8.82) was approximately fivefold higher than in canine aorta (pA2 = 8.18).[1];Long-term (8 months) oral administration of ME3221 (10 mg/kg/d) to aged (32 weeks) stroke-prone hypertensive rats (SHRSP) suppressed mortality and hypertensive complications observed in control SHRSP: stroke (hemorrhage, spongiosis and flaccidity in the cerebral cortex), increased proteinuria, total N-acetyl-β-D-glucosaminidase activity and cardiac hypertrophy and pleural effusion. [2]；SHRSP were orally administered ME3221 (3 and 10 mg/kg per day) from 6 to 20 weeks, and ME3221 inhibited to a considerable extent the elevation of SBP in salt-containing SHRSP, increased survival to >90%, and reduced hypertensive complications such as stroke (moderate), renal injury (increased proteinuria and total N-acetyl-β-D-glucosaminidase activity), and heart failure (cardiac hypertrophy and pleural effusion). [3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | ME-3221 | AT1 receptor |
| Inhibitors Related | H-ASP-PHE-OH | Losartan potassium | Tranilast | Telmisartan | Lisinopril dihydrate | Sacubitril/Valsartan | Ursodeoxycholic acid | Benzyl benzoate | Irbesartan | Losartan | Diisononyl phthalate | Captopril |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Inhibitor Library | Endocrinology-Hormone Compound Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
|
VIP3Y
|
Sichuan HongRi Pharma-Tech Co.,Ltd
|
2026-07-03 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY